HSP90AA1 and melanoma: Clinical trials have demonstrated that combining luminespib with ALK inhibitors in ALK inhibitor-resistant non-small cell lung cancer (NSCLC) improved the clinical response, and that HSP90 inhibitors also restored sensitivity to BRAF/MEK inhibitors in resistant melanoma models [31,32,33].